# E2F7

## Overview
E2F7 is a gene that encodes the E2F transcription factor 7, an atypical member of the E2F family of transcription factors. Unlike other E2F proteins, E2F7 is characterized by its unique structure, which includes two DNA-binding domains and the absence of a dimerization partner binding domain, allowing it to function independently as a transcriptional repressor. The E2F transcription factor 7 plays a critical role in regulating the cell cycle and maintaining genomic stability by repressing genes involved in DNA replication and cell cycle progression. It is particularly significant in the DNA damage response, where it is up-regulated in a p53-dependent manner to enforce cell cycle arrest. E2F7's involvement in various cancers, such as pancreatic cancer and uterine corpus endometrial carcinoma, underscores its clinical significance, although somatic mutations in the gene are not commonly observed (Tan2023Expression; Aksoy2012The; Carvajal2012E2F7).

## Structure
E2F7 is an atypical member of the E2F family of transcription factors, characterized by its unique structural features. Unlike typical E2Fs, E2F7 contains two distinct DNA-binding domains (DBDs) and lacks the dimerization partner (DP) binding domain, pocket protein binding regions, and transcriptional activation domains found in other E2Fs (Xie2021Emerging; Carvajal2012E2F7). These DBDs allow E2F7 to bind DNA as homodimers or heterodimers, enabling it to function as a transcriptional repressor independently of pocket proteins (Emanuele2020Complex; Xie2021Emerging).

E2F7 can undergo alternative splicing to produce two isoforms, E2F7a and E2F7b, which may contribute to its functional diversity (Xie2021Emerging). The protein's structure is crucial for its role in transcriptional repression and regulation of cell cycle-related genes, as well as its involvement in the DNA damage response (Carvajal2012E2F7). E2F7's structural independence from the Rb family allows it to participate in an autoregulatory loop with E2F1, repressing E2F1-dependent transcription (Carvajal2012E2F7). The absence of interaction with Rb family members further highlights its atypical nature within the E2F repressor subgroup (Carvajal2012E2F7).

## Function
E2F7 is an atypical member of the E2F family of transcription factors, functioning primarily as a transcriptional repressor. It plays a crucial role in regulating the cell cycle by inhibiting genes necessary for DNA replication and cell cycle progression. Unlike typical E2F proteins, E2F7 contains two DNA-binding domains and does not require dimerization with DP proteins, allowing it to bind DNA independently (Carvajal2012E2F7).

E2F7 is up-regulated in response to DNA damage in a p53-dependent manner, contributing to the transcriptional repression of a subset of p53 target genes involved in DNA replication, such as E2F1, RRM2, and DHFR. This activity is essential for maintaining genomic stability and enforcing cell cycle arrest following DNA damage (Carvajal2012E2F7). E2F7's role in the DNA damage response includes mediating an anti-proliferative effect, which is independent of p53 status, indicating its downstream role from p53 (Carvajal2012E2F7).

In the context of cellular senescence, E2F7 compensates for the loss of the retinoblastoma protein (RB) by repressing mitosis-related genes, thereby maintaining cell cycle checkpoints and preventing aberrant proliferation in RB-deficient cells (Aksoy2012The). E2F7 is active in the nucleus, where it binds selectively to E2F-responsive promoters, reinforcing its role as a critical regulator of cell cycle progression and genomic stability (Carvajal2012E2F7).

## Clinical Significance
Alterations in the expression and function of the E2F7 gene have been implicated in various cancers. In pancreatic cancer, E2F7 is located in a chromosomal region frequently deleted, and its underexpression is associated with poor prognosis and resistance to platinum-based chemotherapy in ovarian cancer (Aksoy2012The). In uterine corpus endometrial carcinoma (UCEC), E2F7 is significantly overexpressed compared to normal tissues, and its hypermethylation is considered a risk factor for developing UCEC. Despite being one of the most frequently altered genes in UCEC, these alterations do not significantly impact overall survival or disease-free survival (Zhang2020Bioinformatics).

In skin cutaneous melanoma (SKCM), E2F7 expression correlates with the pathological stage of the disease, suggesting its potential as a prognostic biomarker (Tan2023Expression). E2F7 also plays a role in ovarian cancer, where it interacts with E2F8 and is involved in pathways related to cell cycle regulation and apoptosis (Zhou2019E2F258). The gene's involvement in these pathways highlights its significance in tumor development and progression. Despite these associations, somatic mutations in E2F7 have not been described, indicating that its activity may not be rate-limiting for tumorigenesis (Aksoy2012The).

## Interactions
E2F7 is an atypical member of the E2F family of transcription factors, characterized by its ability to function as a transcriptional repressor independently of the retinoblastoma protein (Rb) family. Unlike typical E2Fs, E2F7 does not require a DP partner to bind DNA and lacks an Rb family-binding domain. It recognizes E2F-binding sequences and participates in an autoregulatory loop with E2F1 by repressing E2F1-dependent transcription (Carvajal2012E2F7).

E2F7 is involved in DNA damage-induced transcriptional repression and is up-regulated by p53 in response to DNA damage. It binds directly to E2F-responsive promoters, such as those of E2F1 and DHFR, as demonstrated by chromatin immunoprecipitation (ChIP) analysis (Carvajal2012E2F7). This binding is significant in both p53-null and wild-type p53-expressing cells, indicating that E2F7's role in transcriptional repression is independent of p53 status (Carvajal2012E2F7).

In neuroblastoma, E2F7 interacts with the SAPCD2 protein, which binds to E2F7 in the cytoplasm, altering its subcellular distribution and promoting neuroblastoma progression by derepressing E2F signaling transactivation (Zhang2022SAPCD2). This interaction suggests that SAPCD2 may influence the function of E2F7 by affecting its localization, leading to an imbalance in E2F7 and E2F1 in the nucleus (Zhang2022SAPCD2).


## References


[1. (Zhang2020Bioinformatics) YunZheng Zhang, Zihao Wang, Jian Ma, JiaNing Huo, YiBing Li, YuShan Wang, Hao Chen, LuHe Shan, and Xiaoxin Ma. Bioinformatics identification of the expression and clinical significance of e2f family in endometrial cancer. Frontiers in Genetics, November 2020. URL: http://dx.doi.org/10.3389/fgene.2020.557188, doi:10.3389/fgene.2020.557188. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2020.557188)

[2. (Aksoy2012The) Ozlem Aksoy, Agustin Chicas, Tianying Zeng, Zhen Zhao, Mila McCurrach, Xiaowo Wang, and Scott W. Lowe. The atypical e2f family member e2f7 couples the p53 and rb pathways during cellular senescence. Genes &amp; Development, 26(14):1546–1557, July 2012. URL: http://dx.doi.org/10.1101/gad.196238.112, doi:10.1101/gad.196238.112. This article has 100 citations.](https://doi.org/10.1101/gad.196238.112)

[3. (Xie2021Emerging) Dan Xie, Qin Pei, Jingyuan Li, Xue Wan, and Ting Ye. Emerging role of e2f family in cancer stem cells. Frontiers in Oncology, August 2021. URL: http://dx.doi.org/10.3389/fonc.2021.723137, doi:10.3389/fonc.2021.723137. This article has 52 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2021.723137)

[4. (Carvajal2012E2F7) Luis A. Carvajal, Pierre-Jacques Hamard, Crystal Tonnessen, and James J. Manfredi. E2f7, a novel target, is up-regulated by p53 and mediates dna damage-dependent transcriptional repression. Genes &amp; Development, 26(14):1533–1545, July 2012. URL: http://dx.doi.org/10.1101/gad.184911.111, doi:10.1101/gad.184911.111. This article has 115 citations.](https://doi.org/10.1101/gad.184911.111)

[5. (Emanuele2020Complex) Michael J. Emanuele, Taylor P. Enrico, Ryan D. Mouery, Danit Wasserman, Sapir Nachum, and Amit Tzur. Complex cartography: regulation of e2f transcription factors by cyclin f and ubiquitin. Trends in Cell Biology, 30(8):640–652, August 2020. URL: http://dx.doi.org/10.1016/j.tcb.2020.05.002, doi:10.1016/j.tcb.2020.05.002. This article has 47 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.tcb.2020.05.002)

[6. (Zhang2022SAPCD2) Zi-Mu Zhang, Hai-Bo Cao, Zhi-Heng Li, Ran Zhuo, Yan-Fang Tao, Xiao-Lu Li, Gen Li, Xin-Mei Liao, Fang Fang, Yi Xie, Di Wu, Hai-Rong Wang, Jian-Wei Wang, Yan-Ling Chen, Juan-Juan Yu, Si-Qi Jia, Ran-Dong Yang, Xin-Yi Guo, Yang Yang, Chen-Xi Feng, Yun-Yun Xu, Guang-Hui Qian, and Jian Pan. Sapcd2 promotes neuroblastoma progression by altering the subcellular distribution of e2f7. Cell Death &amp; Disease, February 2022. URL: http://dx.doi.org/10.1038/s41419-022-04624-z, doi:10.1038/s41419-022-04624-z. This article has 7 citations.](https://doi.org/10.1038/s41419-022-04624-z)

[7. (Tan2023Expression) Liuchang Tan. Expression pattern and clinical significance of e2f transcription factors in skin cutaneous melanoma. Journal of Women’s Health and Development, 2023. URL: http://dx.doi.org/10.26502/fjwhd.2644-288400104, doi:10.26502/fjwhd.2644-288400104. This article has 0 citations.](https://doi.org/10.26502/fjwhd.2644-288400104)

[8. (Zhou2019E2F258) Quan Zhou, Fan Zhang, Ze He, and Man-Zhen Zuo. E2f2/5/8 serve as potential prognostic biomarkers and targets for human ovarian cancer. Frontiers in Oncology, March 2019. URL: http://dx.doi.org/10.3389/fonc.2019.00161, doi:10.3389/fonc.2019.00161. This article has 52 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2019.00161)